Skip to main content
12/18/2019

Latiglutenase for Celiac Disease Shows Symptom, Quality of Life Improvement

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…

Continue Reading
12/13/2019

Marilyn’s Message

As I return to Los Angeles, I would like to take a moment to share with you some of the highlights of our productive two days in Washington, DC. Your consistent support has allowed us to reach this tipping point, and I want to be clear about what your gifts of time, money, and advocacy…

Continue Reading
11/20/2019

Role of Gluten Consumption in Childhood Celiac Disease Development

Within the last year, at least three studies were conducted with the goal of determining the relationship between the amount of gluten ingested and the risk of developing celiac disease. An important review of these studies, conducted by Jonas Ludvigsson and CDF Research Committee Member Benjamin Lebwohl, concluded that new clinical trials must be conducted…

Continue Reading
11/20/2019

Gluten-Free Diet & Weight Changes

Researchers at the Beth Israel Deaconess Medical Center, including Celiac Disease Foundation Medical Advisory Board Member Dan Leffler, conducted a study to determine the effects of the gluten-free diet (GFD) on weight changes in celiac patients after diagnosis. The authors note that while weight gain would be welcome and expected in initially underweight patients, similar…

Continue Reading